AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated ecosystem. As a CDMO with HPAPI capabilities from gram to tons, AGC has systematically adapted its entire development and manufacturing chain to OEB5 standards (0.1–1 µg/m³ over an 8-hour shift), from its new R&D facility through laboratory to commercial production, ensuring consistent containment capabilities throughout the entire process.